PURE Bioscience, Inc.
PURE
$0.08
$0.000.60%
OTC PK
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 29.27% | 31.00% | 12.18% | -8.56% | -9.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.27% | 31.00% | 12.18% | -8.56% | -9.48% |
| Cost of Revenue | 24.58% | 21.52% | 10.85% | -10.19% | -15.64% |
| Gross Profit | 32.63% | 37.97% | 13.11% | -7.35% | -4.49% |
| SG&A Expenses | -13.85% | -17.63% | -18.14% | -17.65% | -12.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.02% | -9.62% | -12.17% | -15.21% | -12.15% |
| Operating Income | 29.42% | 33.57% | 27.44% | 19.56% | 13.84% |
| Income Before Tax | 30.29% | 34.20% | 28.39% | 22.15% | 14.95% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 30.29% | 34.20% | 28.39% | 22.15% | 14.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.29% | 34.20% | 28.39% | 22.15% | 14.95% |
| EBIT | 29.42% | 33.57% | 27.44% | 19.56% | 13.84% |
| EBITDA | 26.61% | 30.27% | 25.13% | 18.77% | 13.99% |
| EPS Basic | 30.58% | 34.68% | 28.57% | 22.39% | 15.24% |
| Normalized Basic EPS | 28.82% | 32.60% | 27.17% | 16.76% | 8.60% |
| EPS Diluted | 30.58% | 34.68% | 28.57% | 22.39% | 15.24% |
| Normalized Diluted EPS | 28.82% | 32.60% | 27.17% | 16.76% | 8.60% |
| Average Basic Shares Outstanding | 0.02% | 0.01% | 0.01% | 0.07% | 0.18% |
| Average Diluted Shares Outstanding | 0.02% | 0.01% | 0.01% | 0.07% | 0.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |